• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Panalgo Partners with COTA to Enhance AI & RWD-Enabled Cancer Care

by Fred Pennic 09/09/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
FDA Extends RCA With COTA to Explore COVID's Effect on Cancer

What You Should Know: 

– Panalgo, a provider of healthcare data analytics solutions, has announced a partnership with COTA, an organization focused on providing real-world data (RWD) for cancer care. 

– The strategic collaboration will enable COTA to make its high-quality hematologic oncology data available through Panalgo’s Instant Health Data Analytics (IHD) platform.

Leveraging COTA’s Real-World Data

COTA’s RWD is derived from electronic health records (EHRs) and offers a comprehensive view of patient journeys. This data can be used to support regulatory submissions and answer research questions related to treatment patterns, real-world outcomes, and care comparisons.

Panalgo’s IHD Analytics platform provides a powerful tool for analyzing healthcare data. With its user-friendly interface and advanced analytics capabilities, IHD enables users to quickly and easily gain insights from their data.

Expanding the Partnership

The initial focus of the partnership will be on hematologic oncology data. However, there are plans to expand the collaboration to include solid tumor data in the future. Additionally, Panalgo and COTA will explore opportunities for research collaborations and AI/technology co-development.

Key benefits of the partnership include:

  • Enhanced Data Access: COTA’s data will be accessible to researchers and analysts through Panalgo’s IHD platform.
  • Improved Insights: The combination of COTA’s high-quality data and Panalgo’s advanced analytics will enable users to gain deeper insights into cancer care.
  • Accelerated Research: Panalgo’s IHD platform can help researchers conduct studies more efficiently and effectively.

“We are delighted to join Panalgo’s data network as their first oncology partner specializing in hematologic cancers,” said COTA’s chief commercial officer, Sandy Leonard. “COTA’s longitudinal, high-quality oncology data enables researchers to generate meaningful insights that support decision making across life science organizations. By leveraging Panalgo’s analytics platform, we can accelerate the speed and eliminate some of the operational barriers to generating these insights.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cancer Diagnostics, Oncology, real-world data (RWD)

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |